Black Rock Inc. Co Diagnostics, Inc. Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Co Diagnostics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 500,050 shares of CODX stock, worth $525,052. This represents 0.0% of its overall portfolio holdings.

Number of Shares

500,050

Previous 501,830 0.35%

Holding current value

$525,052

Previous $667,000 16.04%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$1.06 - $1.42 $1,886 - $2,527	-1,780 Reduced 0.35%	500,050 $560,000
Q4 2023 Feb 13, 2024	SELL	$1.0 - $1.5 $878 - $1,317	-878 Reduced 0.17%	501,830 $667,000
Q3 2023 Nov 13, 2023	SELL	$1.03 - $1.85 $3,915 - $7,031	-3,801 Reduced 0.75%	502,708 $532,000
Q2 2023 Aug 11, 2023	BUY	$1.04 - $1.64 $5,098 - $8,039	4,902 Added 0.98%	506,509 $562,000
Q1 2023 May 12, 2023	SELL	$1.39 - $3.24 $52,158 - $121,577	-37,524 Reduced 6.96%	501,607 $742,000

Q4 2022 Feb 13, 2023	SELL	$2.32 - $3.68 $1,076 - $1,707	-464 Reduced 0.09%	539,131 $1.36 Million
Q3 2022 Nov 14, 2022	BUY	$2.87 - $7.01 $108,925 - $266,050	37,953 Added 7.57%	539,595 $1.73 Million
Q2 2022 Aug 12, 2022	BUY	$3.76 - $6.29 $53,256 - $89,091	14,164 Added 2.91%	501,642 $2.81 Million
Q1 2022 May 12, 2022	SELL	$5.03 - $9.61 $14,929 - $28,522	-2,968 Reduced 0.61%	487,478 $3.01 Million
Q4 2021 Feb 10, 2022	SELL	$8.12 - $10.37 $331,458 - $423,303	-40,820 Reduced 7.68%	490,446 $4.38 Million
Q3 2021 Nov 09, 2021	BUY	$7.48 - $11.38 $99,693 - $151,672	13,328 Added 2.57%	531,266 $5.17 Million
Q2 2021 Aug 11, 2021	BUY	$7.16 - $9.56 $3.71 Million - $4.95 Million	517,938 New	517,938 $4.27 Million

Others Institutions Holding CODX

# of Institutions

Shares Held

4.23M

Call Options Held

22.9K

Put Options Held

30.4K

View Full List

About Co-Diagnostics, Inc.

Ticker CODX
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 33,781,000
Market Cap $35.5M
Description
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and ...

More about CODX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account